BAY-1895344 is an inhibitor of ataxia-telangiectasia and Rad3-related protein (ATR) kinase that inhibits proliferation in a panel of human tumor cell lines (mean IC50 = 78 nM).1 It halts tumor growth in ovarian and colorectal mouse xenograft models and induces complete tumor remission in mantle cell lymphoma mouse xenograft models. BAY-1895344 also exhibits synergistic anti-tumor activity with radium-223 in a mouse xenograft model of castration-resistant prostate cancer bone metastases.
1.Wengner, A.M., Siemeister, G., Luecking, U., et al.Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor modelsCancer Res.77(13 Suppl)836-836(2017)